Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Recruiting 5Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 112Genitourinary 55Thoracic 46Lymphoid 33Gynecologic 27Breast 26Head & Neck 21Sarcoma 11Tumor-Agnostic 6Other solid neoplasm 5Other hematologic neoplasm 5Dermatologic 5CNS 5Myeloid 1

Conditions

Neoplasm Metastasis 4Neoplasms 3

Interventions

pembrolizumab 24Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 19Paclitaxel 11Standard of Care 10Bevacizumab 10atezolizumab 9Carboplatin 9Nivolumab 8Cisplatin 8Blood Specimen Collection 8Surveys and Questionnaires 7Capecitabine 7Radiosurgery 6Pemetrexed 6Gemcitabine 6Cyclophosphamide 6durvalumab 5Taxes 5Irinotecan 5trastuzumab deruxtecan 4olaparib 4niraparib 4cabozantinib 4X-Rays 4Radiotherapy 4Oxaliplatin 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Gemcitabine × Tumor-Agnostic × 90 days × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

National Cancer Institute, Naples

Phase 2 Recruiting
240 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06790602 2026-04-09

SWITCH

University of California, San Diego

Phase 2 Recruiting
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡